Long-term disease-free survival in immature teratoma of the ovary

Abstract

Long‐term follow‐up on five patients with immature teratoma of the ovary with residual metastatic Grade 0 disease following chemotherapy is reported. All five patients are free of progressive disease 40–96 months following original diagnosis. The concept of ‘retroconversion’ following chemotherapy for immature teratoma of the ovary is reemphasized. Cancer 50:159–162, 1982.

Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease

“…Sixteen references were excluded after obtaining the full text for the following reasons: Nine references (Chang 1994; Dimopoulos 1998; Hong 1998; Lian 1996; Mayordomo 1994; Mitchell 1999; Nawa 2001; Schwartz 1992; Segelov 1994 ) were studies that included females less than the age of 18 years where it was not possible to distinguish between adults and children. Hence, these studies did not fulfil our age criteria for inclusion.Two references (Culine 1995; Lokey 1981) were correspondence letters and did not include any studies which met our inclusion criteria.Four references (Dara 1982; Goto 1987; Linasmita 1998;Singh 1988) were case series of less than 20 patients (5, 2, 18, and 10 respectively) so did not meet our criteria for inclusion.One reference (Zhang 1998) did not have a suitable comparison group.…”

“…Four references (Dara 1982; Goto 1987; Linasmita 1998;Singh 1988) were case series of less than 20 patients (5, 2, 18, and 10 respectively) so did not meet our criteria for inclusion.…”

“…The analyses do not report by age or use statistical adjustment and it was not possible to perform our own analyses as only a subset of individual patient data is available Culine 1995 Comparison of AVAB versus VAB-6 regimens in 21 patients was available as individual patient data were available which reported age, recurrent disease, treatment group and survival times. However, after exclusion of children there was only a comparison of 4 patients who received AVAB and two who received VAB for recurrent disease and 4 who were given AVAB versus five patients given VAB as primary adjuvant therapy Dara 1982 Only five patients in case series Dimopoulos 1998 Study included children where the median age was 20 years (range 12 to 69 years) and could not be distinguished from adults Goto 1987 Report comprises of only two patients Hong 1998 Study included children where the median age was 23.3 years (range: 7 to 62 years) Lian 1996 Study does not examine women with GCT Linasmita 1998 Only 18 women were included in this case series Lokey 1981 Letter of correspondence Mayordomo 1994 Study included children where the median age was 20 years (range 6 to 68 years) and could not be distinguished from adults Mitchell 1999 The study reports an adjusted hazard ratio for overall survival for platinum versus non-platinum based chemotherapy, but does not report by age. The median age was 21 years (range, 4 to 44 years), so a high proportion of children will have been included in the study Nawa 2001 The study reports comparisons of different chemotherapy regimens for treatment of malignant ovarian germ cell tumours with yolk sac histology, but does not report by age.…”